Tech transfer
Molecular Gate S.L., new ICMAB-CSIC and BeAble Capital spin-off, offers a transformative technology to ensure the authenticity of pharmaceutical products
Molecular Gate S.L. aims to become a key player in the anti-counterfeiting industry, particularly in the health sector. The cost-effective security technology developed by the company will ensure the authenticity of pharmaceutical products using smart optical printed elements on the products.


How would you ensure that the medicine you buy is not fake? Currently, a very large fraction of medicines sold worldwide are counterfeit. These include false products obtained from fraudulent online retailers, diluted drugs and medicines with altered composition, or even pills whose authenticity cannot be traced once the package is removed. All of these constitute an important health risk for consumers and patients.
Can you imagine a way to ensure that these medical products are authentic?
The new spin-off, Molecular Gate S.L, created by researchers Mariano Campoy-Quiles and Aleksandr Perevedentsev from the Institute of Materials Science of Barcelona (ICMAB-CSIC), aims to provide a range of unique and cost-effective security solutions for the pharmaceutical market, which will help to verify the authenticity of products such as vaccines, and ensure their proper handling during storage and transportation. Researchers envisage that the technology “will not only enable straightforward visual and machine-readable verification, but will also be near-impossible to counterfeit by alternative methods”.
The spin-off has been created together with BeAble Capital team, a fund manager specialized in Science Equity (technology transfer in Deep Science) who, as well as providing the necessary investment, will support the company in shaping the business strategy to exploit the niche in the market.

Molecular Gate S.L. technology | ICMAB-CSIC
The technology that this spin-off will develop consists of creating anti-counterfeit elements for the packaging typically used in the pharmaceutical industry, including bottles and blisters, to ensure that the contained products are authentic. This is vitally important not only for the final consumer to guarantee that they are taking the authentic medicine with certified effectiveness, but also for the pharmaceutical companies themselves in order to safeguard their reputation in the marketplace.
“The existing security solutions in the market have numerous limitations; they are often expensive and bulky, and most require UV-free or cold-chain handling, which introduce transportation and end-use constrains” explains Aleksandr Perevedentsev. Moreover, most current solutions only target security either at the “company” level, by adding a hidden security feature to authenticate the packaging if required. “Customer”-level security is more desirable and versatile, but simultaneously more difficult to implement since holograms are now considered insufficiently secure while other security solutions are often too expensive to produce or require specialized hardware or software for verification.
Molecular Gate S.L. aims to provide a two-level anti-counterfeiting technology, both for consumers and companies, with a single printed element on the pharmaceutical products, which can be easily scanned using a mobile phone, but is almost impossible to replicate since it requires the patented technology licensed from CSIC to the company.

Mariano Campoy-Quiles and Aleksandr Perevedentsev, founders of Molecular Gate S.L. CSIC spin-off | ICMAB-CSIC
The technology is based on a unique and versatile method to control the nanostructure, molecular orientation and composition of different materials and thin films at local level, with high speed and resolution.
“While thinking of potential applications of this technology, we remembered the work of our friend and colleague Prof. Paul Smith (ETH Zurich), who introduced polarizing elements as security features in the Swiss bank notes” explains Mariano Campoy-Quiles. “We realized that we could go one step further on that field, as our technology allowed writing patterns and drawings that were polarized in different directions, i.e. with polymer chains oriented in different directions at the micrometer scale”.
The idea is, as with an invisible ink, that the patterned security element is only revealed when observed with a simple polarizing system like a mobile phone camera, while remaining invisible to the naked eye.
This technology is protected by the patent WO2021254932 “Method for providing a structural and/or compositional modification in a molecular semiconductor target film” filed by CSIC in 2020, whose inventors are the two researchers mentioned previously.
Mariano Campoy-Quiles and Aleksandr Perevedentsev, founders of Molecular Gate S.L. CSIC spin-off, showing the anti-counterfeiting technology | ICMAB-CSIC
Press
- Una empresa surgida del CSIC desarrolla una tecnología para impedir la falsificación de fármacos (CSIC, 17 March 2022)
- Molecular Gate, nueva spin-off del ICMAB-CSIC y BeAble Capital, ofrece una transformadora tecnología que asegura la autenticidad de los productos farmacéuticos (CSIC Cat, 17 March 2022)
- Molecular Gate, nova spin-off de l’ICMAB-CSIC i BeAble Capital, ofereix una transformadora tecnologia per assegurar l’autenticitat dels productes farmacèutics (CSIC Cat, 17 March 2022)
- Una empresa surgida del CSIC desarrolla una tecnología para impedir la falsificación de fármacos (InfoSalus, 17 March 2022)
- Una empresa surgida del CSIC crea una tecnología que evita la falsificación de fármacos (ConSalud.es, 17 March 2022)
- Molecular Gate S.L., nova spin-off de l'ICMAB-CSIC i BeAble Capital (PRUAB, 17 March 2022)
- Una spin-off del CSIC desarrollará una nueva tecnología para verificar la autenticidad de los medicamentos (PharmaMarket, 18 March 2022)
- Aumentar la seguridad en el fraude de medicamentos, objetivo de una empresa surgida del CSIC (Gaceta Médica, 18 March 2022)
- Nanotecnología para impedir la falsificación de fármacos (El Global, 18 March 2022)
- CSIC spin-off company develops technology to prevent drug counterfeiting (Bionity, 21 March 2022)
- Una empresa surgida del CSIC desarrolla una tecnología para impedir la falsificación de fármacos (Salud a Diario, 17 March 2022)
- Molecular Gate S.L., nueva spin-off del ICMAB-CSIC y BeAble Capital, ofrece una transformadora tecnología para asegurar la autenticidad de los productos farmacéuticos (ASCRI, 17 March 2022)
- Molecular Gate, la spin-off del CSIC que usa nanotecnología para impedir la falsificación de fármacos (Farma Industrial, 18 March 2022)
- BeAble Capital da impulso a la nueva ‘spin off’ del CSIC: Molecular Gate (Planta Doce, 21 March 2022)